Compare XPL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | IMMP |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.1M | 61.4M |
| IPO Year | 2000 | 2012 |
| Metric | XPL | IMMP |
|---|---|---|
| Price | $0.78 | $0.41 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $1.20 | ★ $5.50 |
| AVG Volume (30 Days) | 72.4K | ★ 179.0K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $0.29 |
| 52 Week High | $0.98 | $3.53 |
| Indicator | XPL | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 53.51 |
| Support Level | $0.70 | $0.35 |
| Resistance Level | $0.79 | $0.46 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 83.61 | 82.75 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.